全文获取类型
收费全文 | 360篇 |
免费 | 32篇 |
专业分类
儿科学 | 15篇 |
妇产科学 | 24篇 |
基础医学 | 38篇 |
口腔科学 | 2篇 |
临床医学 | 85篇 |
内科学 | 77篇 |
皮肤病学 | 1篇 |
神经病学 | 9篇 |
特种医学 | 5篇 |
外科学 | 31篇 |
综合类 | 51篇 |
预防医学 | 32篇 |
眼科学 | 1篇 |
药学 | 12篇 |
肿瘤学 | 9篇 |
出版年
2023年 | 3篇 |
2022年 | 5篇 |
2021年 | 14篇 |
2020年 | 4篇 |
2019年 | 7篇 |
2018年 | 5篇 |
2017年 | 5篇 |
2016年 | 10篇 |
2015年 | 6篇 |
2014年 | 9篇 |
2013年 | 14篇 |
2012年 | 21篇 |
2011年 | 17篇 |
2010年 | 14篇 |
2009年 | 5篇 |
2008年 | 16篇 |
2007年 | 15篇 |
2006年 | 13篇 |
2005年 | 18篇 |
2004年 | 10篇 |
2003年 | 20篇 |
2002年 | 7篇 |
2001年 | 12篇 |
2000年 | 8篇 |
1999年 | 9篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1993年 | 3篇 |
1992年 | 6篇 |
1991年 | 4篇 |
1988年 | 3篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1983年 | 5篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1968年 | 8篇 |
1954年 | 2篇 |
1949年 | 2篇 |
1945年 | 2篇 |
1942年 | 2篇 |
1933年 | 4篇 |
1932年 | 5篇 |
1931年 | 4篇 |
1929年 | 2篇 |
1928年 | 5篇 |
1927年 | 4篇 |
1926年 | 3篇 |
1925年 | 5篇 |
1923年 | 2篇 |
排序方式: 共有392条查询结果,搜索用时 15 毫秒
311.
312.
313.
314.
315.
316.
317.
318.
319.
Objectives: Although recommendations for preventing occupational heat-related illness among farmworkers include hydration and cooling practices, the extent to which these recommendations are universally practiced is unknown. The objective of this analysis was to compare hydration and cooling practices between farmworkers in Oregon and Washington. Methods: A survey was administered to a purposive sample of Oregon and Washington farmworkers. Data collected included demographics, work history and current work practices, hydration practices, access and use of cooling measures, and headwear and clothing worn. Results: Oregon farmworkers were more likely than those in Washington to consume beverages containing sugar and/or caffeine. Workers in Oregon more frequently reported using various cooling measures compared with workers in Washington. Availability of cooling measures also varied between the two states. Conclusions: These results highlight the large variability between workers in two states regarding access to and use of methods to stay cool while working in the heat. 相似文献
320.
Juan P. Frias Enzo Bonora Luis Nevarez Ruiz Ying G. Li Zhuoxin Yu Zvonko Milicevic Raleigh Malik M. Angelyn Bethel David A. Cox 《Diabetes care》2021,44(3):765
OBJECTIVETo compare efficacy and safety of dulaglutide at doses of 3.0 and 4.5 mg versus 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin.RESEARCH DESIGN AND METHODSPatients were randomly assigned to once-weekly dulaglutide 1.5 mg, 3.0 mg, or 4.5 mg for 52 weeks. The primary objective was determining superiority of dulaglutide 3.0 mg and/or 4.5 mg over 1.5 mg in HbA1c reduction at 36 weeks. Secondary superiority objectives included change in body weight. Two estimands addressed efficacy objectives: treatment regimen (regardless of treatment discontinuation or rescue medication) and efficacy (on treatment without rescue medication) in all randomly assigned patients.RESULTSMean baseline HbA1c and BMI in randomly assigned patients (N = 1,842) was 8.6% (70 mmol/mol) and 34.2 kg/m2, respectively. At 36 weeks, dulaglutide 4.5 mg provided superior HbA1c reductions compared with 1.5 mg (treatment-regimen estimand: −1.77 vs. −1.54% [−19.4 vs. −16.8 mmol/mol], estimated treatment difference [ETD] −0.24% (−2.6 mmol/mol), P < 0.001; efficacy estimand: −1.87 vs. −1.53% [−20.4 vs. −16.7 mmol/mol], ETD −0.34% (−3.7 mmol/mol), P < 0.001). Dulaglutide 3.0 mg was superior to 1.5 mg for reducing HbA1c, using the efficacy estimand (ETD −0.17% [−1.9 mmol/mol]; P = 0.003) but not the treatment-regimen estimand (ETD −0.10% [−1.1 mmol/mol]; P = 0.096). Dulaglutide 4.5 mg was superior to 1.5 mg for weight loss at 36 weeks for both estimands (treatment regimen: −4.6 vs. −3.0 kg, ETD −1.6 kg, P < 0.001; efficacy: −4.7 vs. −3.1 kg, ETD −1.6 kg, P < 0.001). Common adverse events through 36 weeks included nausea (1.5 mg, 13.4%; 3 mg, 15.6%; 4.5 mg, 16.4%) and vomiting (1.5 mg, 5.6%; 3 mg, 8.3%; 4.5 mg, 9.3%).CONCLUSIONSIn patients with type 2 diabetes inadequately controlled by metformin, escalation from dulaglutide 1.5 mg to 3.0 mg or 4.5 mg provided clinically relevant, dose-related reductions in HbA1c and body weight with a similar safety profile. 相似文献